The Technical Analyst
Mersana Therapeutics Inc [MRSN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Mersana Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.04% $2.85
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 343.66 mill |
| EPS: | -1.760 |
| P/E: | -1.620 |
| Earnings Date: | Feb 26, 2024 |
| SharesOutstanding: | 120.58 mill |
| Avg Daily Volume: | 2.22 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.620 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.28x |
| Company: PE -1.620 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.203 (-142.21%) $-4.05 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.46 - 3.24 ( +/- 13.79%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Alleva Lawrence M | Buy | 3 996 | Stock Option (right to buy) |
| 2024-01-13 | Mandelia Ashish | Buy | 0 | |
| 2024-01-15 | Protopapas Anna | Buy | 17 708 | Common Stock |
| 2024-01-15 | Protopapas Anna | Buy | 21 250 | Common Stock |
| 2024-01-16 | Protopapas Anna | Sell | 29 399 | Common Stock |
| INSIDER POWER |
|---|
| 74.95 |
| Last 98 transactions |
| Buy: 4 017 838 | Sell: 585 969 |
Forecast:
16:00 - $2.85
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.85
Forecast 2: 16:00 - $2.85
Forecast 3: 16:00 - $2.85
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.85 (-1.04% ) |
| Volume | 1.996 mill |
| Avg. Vol. | 2.22 mill |
| % of Avg. Vol | 89.95 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MRSN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.15 | N/A | Active |
|---|
MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-04 16:30:00 - Press Release
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass., april 04, 2024 (globe newswire) -- mersana therapeutics, inc. (nasdaq:mrsn), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (adcs) targeting cancers in areas of high unmet medical need, today announced that on april 1, 2024, an authorized sub-committee of the board of directors of mersana granted an inducement award, consisting of a restricted stock unit (rsu) award to acquire 35,100 shares of its common stock, to one new employee whose employment commenced in march 2024. the award was granted as an inducement material to the new employee entering employment with mersana in accordance with nasdaq listing rule 5635(c)(4).
2024-02-28 07:00:00 - Press Release
Mersana Therapeutics Provides Business Update And Announces fourth Quarter And Full Year 2023 Financial Results
Cambridge, mass., feb. 28, 2024 (globe newswire) -- mersana therapeutics, inc. (nasdaq: mrsn), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (adcs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended december 31, 2023.
2024-02-27 08:01:00 - Press Release
Mersana Therapeutics To Present At Upcoming Investor Conferences
Cambridge, mass., feb. 27, 2024 (globe newswire) -- mersana therapeutics, inc. (nasdaq: mrsn), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (adcs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:
2024-02-21 08:00:00 - Press Release
Mersana Therapeutics To Host Fourth Quarter And Year End 2023 Conference Call On February 28, 2024
Cambridge, mass., feb. 21, 2024 (globe newswire) -- mersana therapeutics, inc. (nasdaq: mrsn), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (adcs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended december 31, 2023 on wednesday, february 28, 2024. the company will host a conference call and webcast at 8:00 a.m. eastern time that morning.
2024-02-01 08:00:00 - Press Release
Mersana Therapeutics To Participate In Guggenheim's 6th Annual Biotechnology Conference
Cambridge, mass., feb. 01, 2024 (globe newswire) -- mersana therapeutics, inc. (nasdaq: mrsn), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (adcs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at guggenheim's 6th annual biotechnology conference on february 8, 2024 at 11:30 a.m. et. a live webcast of this event will be available on the investors & media section of mersana's website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event.
Latest News
2024-02-28 14:10:06 - Seeking Alpha
Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript
2024-02-28 09:11:16 - Zacks Investment Research
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.44 per share a year ago.
2024-02-27 08:01:00 - GlobeNewsWire
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:
2024-02-21 08:00:00 - GlobeNewsWire
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
2024-02-20 11:06:44 - Zacks Investment Research
Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-01-22 17:41:45 - InvestorPlace
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with substantial catalysts and make a fortune.
2023-10-31 16:30:00 - GlobeNewsWire
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
2023-08-18 11:05:02 - Zacks Investment Research
After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN)
The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-08-16 10:59:50 - Zacks Investment Research
Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-08-08 11:25:54 - Zacks Investment Research
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.55 per share a year ago.